Safety Alerts & Recalls
What does this mean?
This recall for Avalide 300 mg/25 mg tablets from Bristol-Myers Squibb and Sanofi-Synthelabo was issued at a warehouse and pharmacy level only. The companies involved believe that any recalled product that may have been dispensed to patients does not pose a significant health risk. However, there is a possibility that these recalled tablets may be less effective at lowering blood pressure. If you take Avalide 300 mg/25 mg tablets and are concerned, you should speak to your doctor.
Bristol-Myers Squibb Co. is Recalling 60 Million Tablets of Avalide
On behalf of the Bristol-Myers Squibb and Sanofi-Synthelabo partnership, Bristol-Myers Squibb Co. is recalling 62 lots of Avalide 300 mg/25 mg tablets because of the possibility that one of the active ingredients in Avalide, irbesartan, may dissolve at a slower than optimal rate. Although a full review of post-marketing safety reports has not shown any evidence that the recalled tablets are less effective at lowering blood pressure, the company has issued the recall because they are unable to rule out that possibility.
Avalide contains the active ingredients irbesartan and hydrochlorothiazide. The recalled tablets contain 300 mg of irbesartan and 25 mg of hydrochlorothiazide. The recalled lot numbers were manufactured before November 2009.
For more information, please visit: more information here